Xellia CEO Questions Key Ingredients Reliance Of US And Europe
As Company Ramps Up US Operations To Strengthen Anti-Infectives Production
Executive Summary
In an exclusive interview with Generics Bulletin, the CEO of API and FDF manufacturer Xellia Pharmaceuticals, expresses concern over supply chain resilience of the US and the EU, as he points out the weaknesses exposed by the pandemic. The company has also announced the release of its first anti-infectives manufactured at its newly operational Cleveland site.